Unknown

Dataset Information

0

A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.


ABSTRACT: Due to superior long-term toxicity profiles, zidovudine (AZT) and tenofovir disoproxil fumarate (TDF) are preferred over stavudine (d4T) for first-line antiretroviral regimens. However, short-term d4T use could be beneficial in avoiding AZT-induced anaemia.We randomized (1:1:1) 150 treatment-naive Thai HIV-infected adults with CD4(+) T-cell count <350 cells/mm(3) to arm 1 (24-week GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)] followed by 48-week GPO-VIR Z250(®) [AZT plus 3TC plus NVP]), arm 2 (72-week GPO-VIR Z250(®)) or arm 3 (72-week TDF plus emtricitabine [FTC] plus NVP). Haemoglobin (Hb), dual energy x-ray absorptiometry, neuropathic signs, estimated glomerular filtration rate (eGFR), CD4(+) T-cell count, plasma HIV RNA and adherence were assessed.In an intention-to-treat analysis, mean Hb decreased from baseline to week 24 in arm 2 compared with arm 1 (-0.19 versus 0.68 g/dl; P=0.001) and arm 3 (0.48 g/dl; P=0.010). Neuropathic signs were more common in arm 2 compared with arm 3 (20.4 versus 4.2%; P=0.028) at week 24. There were no differences in changes in peripheral fat and eGFR from baseline to weeks 24 and 72 among arms. CD4(+) T-cell count increased more in arm 1 than arms 2 and 3 from baseline to week 24 (168 versus 117 and 118 cells/mm(3); P=0.01 and 0.02, respectively) but the increase from baseline to week 72 was similar among arms.A 24-week d4T lead-in therapy caused less anaemia and greater initial CD4(+) T-cell count increase than initiating treatment with AZT. This strategy could be considered in patients with baseline anaemia or low CD4(+) T-cell count. If confirmed in a larger study, this may guide global recommendations on antiretroviral initiation where AZT is more commonly used than TDF.

SUBMITTER: Phanuphak N 

PROVIDER: S-EPMC3715552 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.

Phanuphak Nittaya N   Ananworanich Jintanat J   Teeratakulpisarn Nipat N   Jadwattanakul Tanate T   Kerr Stephen J SJ   Chomchey Nitiya N   Hongchookiat Piranun P   Mathajittiphun Pornpen P   Pinyakorn Suteeraporn S   Rungrojrat Patcharawee P   Praihirunyakit Pairoa P   Gerschenson Mariana M   Phanuphak Praphan P   Valcour Victor V   Kim Jerome H JH   Shikuma Cecilia C  

Antiviral therapy 20121207 8


<h4>Background</h4>Due to superior long-term toxicity profiles, zidovudine (AZT) and tenofovir disoproxil fumarate (TDF) are preferred over stavudine (d4T) for first-line antiretroviral regimens. However, short-term d4T use could be beneficial in avoiding AZT-induced anaemia.<h4>Methods</h4>We randomized (1:1:1) 150 treatment-naive Thai HIV-infected adults with CD4(+) T-cell count <350 cells/mm(3) to arm 1 (24-week GPO-VIR S30(®) [d4T plus lamivudine (3TC) plus nevirapine (NVP)] followed by 48-w  ...[more]

Similar Datasets

| S-EPMC7710557 | biostudies-literature
| S-EPMC6358196 | biostudies-literature
| S-EPMC6905402 | biostudies-literature
| S-EPMC5766122 | biostudies-literature
| S-EPMC10976086 | biostudies-literature
| S-EPMC8020360 | biostudies-literature
| S-EPMC3855348 | biostudies-literature
| S-EPMC6355823 | biostudies-literature
| S-EPMC10394723 | biostudies-literature
| S-EPMC8118264 | biostudies-literature